How are you taking part in this consultation?

You will not be able to change how you comment later.

You must be signed in to answer questions

  • Question on Consultation

    Has all of the relevant evidence been taken into account?

  • Question on Consultation

    Are the summaries of clinical and cost effectiveness reasonable interpretations of the evidence?

  • Question on Consultation

    Are the recommendations sound and a suitable basis for guidance to the NHS?
The content on this page is not current guidance and is only for the purposes of the consultation process.

Idelalisib for treating refractory follicular lymphoma

Closed for comments This consultation ended on at   Request commenting lead permission

1 Recommendations

1.1 Idelalisib is not recommended, within its marketing authorisation, for treating follicular lymphoma that has not responded to 2 previous lines of treatment in adults.

1.2 This recommendation is not intended to affect treatment with idelalisib that was started in the NHS before this guidance was published. People having treatment outside this recommendation may continue without change to the funding arrangements in place for them before this guidance was published, until they and their NHS clinician consider it appropriate to stop.

Why the committee made these recommendations

The options after 2 lines of treatment for follicular lymphoma include a range of chemotherapy treatments. The choice of the specific treatment depends on what the person has had already.

Idelalisib has not been compared directly with current chemotherapy treatments. So, it is unclear whether it is better, and if so by how much, than what the NHS currently offers.

It is therefore not possible to reliably estimate the cost effectiveness of idelalisib. Because of this, idelalisib cannot be recommended for routine use in the NHS or for inclusion in the Cancer Drugs Fund.